search button

NK cell‑produced IFN‑γ regulates cell growth and apoptosis of colorectal cancer by regulating IL‑15

  • Authors:
    • Feng Cui
    • Di Qu
    • Ruya Sun
    • Mingming Zhang
    • Kejun Nan

  • View Affiliations

  • Published online on: December 18, 2019     https://doi.org/10.3892/etm.2019.8343
  • Pages: 1400-1406
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Globally, colorectal cancer (CC) is the third leading cause of mortality associated with cancer. Natural killer (NK) cells are a major class of cells that are responsible for eliminating tumor cells and cytokine production. NK cell‑mediated production of interferon gamma (IFN‑γ) has antiviral, immunoregulatory and anti‑tumor properties. IL‑15 is important in linking inflammation with cancer. For instance, IL‑15 promotes humoral and cell‑mediated immune responses to inhibit tumor growth. IL‑15 inhibits colitis‑associated colon carcinogenesis by inducing antitumor immunity. However, the effect of NK cell‑mediated IFN‑γ on IL‑15 expression in CC progression remains unknown. mRNA and protein level were detected using reverse transcription‑quantitative PCR and western blotting, respectively. IFN‑γ concentrations were detected using ELISAs. The cytotoxicity of NK‑92 cells on SW480 cells was detected using cytoTox 96® non‑radioactive cytotoxicity assays. Cell apoptosis and cell proliferation was detected using flow cytometry and CCK‑8 assays, respectively. IL‑2 was used for NK‑92 stimulation, IL‑15 antibodies were used to neutralize IL‑15 bioactivity. For the present study, 21 patients with CC and 21 healthy volunteers were enrolled at the First Affiliated Hospital of Xi'an Jiaotong University. IL‑15 mRNA and protein expression were significantly lower in NK cells isolated from the CC group compared with healthy volunteer group. IL‑2 enhanced the production/secretion of IFN‑γ in addition to enhancing NK‑92 cell‑mediated killing of SW480 cells. Compared with the control group, NK‑92 cells treated with IL‑2 alone significantly increased cell apoptosis, BAX expression levels as well as phosphorylated (p)‑Janus kinase 2 and p‑STAT1 protein levels, whilst reducing cell viability and Bcl‑2 protein levels in SW480 cells. These observations were not made when treated with IL‑2 and polyclonal antibody (pAb) targeting IL‑15. Taken together, NK cell‑mediated IFN‑γ served a pivotal role in CC by regulating IL‑15. The effects of IL‑2 induced IFN‑γ were abolished by pAb IL‑15 treatment. The mechanisms of action behind how IFN‑γ regulates IL‑2 is unclear, and is a promising area for future research.
View Figures
View References

Related Articles

Journal Cover

February-2020
Volume 19 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Cui F, Qu D, Sun R, Zhang M and Nan K: NK cell‑produced IFN‑γ regulates cell growth and apoptosis of colorectal cancer by regulating IL‑15. Exp Ther Med 19: 1400-1406, 2020.
APA
Cui, F., Qu, D., Sun, R., Zhang, M., & Nan, K. (2020). NK cell‑produced IFN‑γ regulates cell growth and apoptosis of colorectal cancer by regulating IL‑15. Experimental and Therapeutic Medicine, 19, 1400-1406. https://doi.org/10.3892/etm.2019.8343
MLA
Cui, F., Qu, D., Sun, R., Zhang, M., Nan, K."NK cell‑produced IFN‑γ regulates cell growth and apoptosis of colorectal cancer by regulating IL‑15". Experimental and Therapeutic Medicine 19.2 (2020): 1400-1406.
Chicago
Cui, F., Qu, D., Sun, R., Zhang, M., Nan, K."NK cell‑produced IFN‑γ regulates cell growth and apoptosis of colorectal cancer by regulating IL‑15". Experimental and Therapeutic Medicine 19, no. 2 (2020): 1400-1406. https://doi.org/10.3892/etm.2019.8343